Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Betta Pharmaceuticals Co Ltd (Betta Pharmaceuticals) is a pharmaceutical company that carries out the research and development of innovative drugs. It primarily focuses on the development of new drugs, particularly in the field of oncology. The company's pipeline products include Conmana, Ensacove, Bevacizumab, BPI-D0316,CM082, Balstilimab, Zalifrelimab, BPI-16350, MRX2843,BPI-361175, MCLA-129, BPI-371153, BPI- 452080, BPI-460372, EYP-1901, CFT8919, BPI-221351, and BPI-520105. Betta Pharmaceuticals' products are used in the treatment of various cancers, including non-small cell lung cancer and renal cell carcinoma. The company operates research and development centers in China and the US. Betta Pharmaceuticals is headquartered in Hangzhou, Zhejiang, China.
Headquarters
China
Address
No.355 Xingzhong Road, Yuhang Economic and Technological Development Zone, Hangzhou, Zhejiang, 311100
Website
www.bettapharma.com
Telephone
86 571 89265665
No of Employees
1,785
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
300558 (SHE)
Revenue (2024)
$502.2M
24.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-24.2%
(2024 vs 2023)
Market Cap*
$4.5B
Net Profit Margin (2024)
XYZ
-39.2%
(2024 vs 2023)
* As of and is in US$
Betta Pharmaceuticals Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Icotinib |
| Ensartinib |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In November, the company entered into an agreement with Hangzhou Ruipu Chenchuang to collaborate in the development of the stem cell therapy business. |
| 2024 | Contracts/Agreements | In September, the company entered into an agreement with Heyuan Biopharma to distribute Aofumin. |
| 2024 | Contracts/Agreements | In June, the company entered into an agreement with Sinopharm Group Co., Ltd. to enhance its capabilities in the healthcare sector, especially in areas such as vaccine distribution, research, and development. |
Competitor Comparison
| Key Parameters | Betta Pharmaceuticals Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Cachet Pharmaceutical Co Ltd | Walvax Biotechnology Co Ltd | EOC Pharma Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Hangzhou | Shanghai | Beijing | Kunming | Shanghai |
| State/Province | Zhejiang | Shanghai | Beijing | Yunnan | Shanghai |
| No. of Employees | 1,785 | 40,603 | 1,741 | 1,981 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ding Lieming | General Manager; Chairman; Chief Executive Officer | Executive Board | 2013 | 63 |
| Tong Jia | Chief Executive Officer; Director | Executive Board | 2021 | 49 |
| Fan Jianxun | Director; Vice President; Chief Financial Officer | Executive Board | 2023 | 55 |
| Li Mao | Chief Medical Officer; Director; President - Research and Development | Executive Board | - | - |
| Jianxun Fan | Vice President; Chief Financial Officer | Senior Management | 2023 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer